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Abstract
Purpose: To evaluate the accuracy of the sub-classification of renal cortical neoplasms using molecular signatures.
Experimental Design: A search of publicly available databases was performed to identify microarray datasets with multiple
histologic sub-types of renal cortical neoplasms. Meta-analytic techniques were utilized to identify differentially expressed
genes for each histologic subtype. The lists of genes obtained from the meta-analysis were used to create predictive
signatures through the use of a pair-based method. These signatures were organized into an algorithm to sub-classify renal
neoplasms. The use of these signatures according to our algorithm was validated on several independent datasets.
Results: We identified three Gene Expression Omnibus datasets that fit our criteria to develop a training set. All of the
datasets in our study utilized the Affymetrix platform. The final training dataset included 149 samples represented by the
four most common histologic subtypes of renal cortical neoplasms: 69 clear cell, 41 papillary, 16 chromophobe, and 23
oncocytomas. When validation of our signatures was performed on external datasets, we were able to correctly classify 68 of
the 72 samples (94%). The correct classification by subtype was 19/20 (95%) for clear cell, 14/14 (100%) for papillary, 17/19
(89%) for chromophobe, 18/19 (95%) for oncocytomas.
Conclusions: Through the use of meta-analytic techniques, we were able to create an algorithm that sub-classified renal
neoplasms on a molecular level with 94% accuracy across multiple independent datasets. This algorithm may aid in
selecting molecular therapies and may improve the accuracy of subtyping of renal cortical tumors.
Citation: Sanford T, Chung PH, Reinish A, Valera V, Srinivasan R, et al. (2011) Molecular Sub-Classification of Renal Epithelial Tumors Using Meta-Analysis of Gene
Expression Microarrays. PLoS ONE 6(7): e21260. doi:10.1371/journal.pone.0021260
Editor: Chad Creighton, Baylor College of Medicine, United States of America
Received December 20, 2010; Accepted May 26, 2011; Published July 27, 2011
This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for
any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.
Funding: This research was supported by the Intramural Research Program of the National Institutes of Health, National Cancer Institute, Center for Cancer
Research. The study was supported by grants from the United States Federal government: 1. Z01 BC011028-01 Molecular Genetics RCC; 2. Z01 BC011038-01 Mol
Ther: VHL and FH; and 3. Z01 BC011043-01 Mol Ther: MET and BHD 10. Z01 BC 011023 Fellowship Training. The U.S. Federal government had no role in study
design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: bratslag@mail.nih.gov
Introduction
Renal epithelial tumors are a diverse group of neoplasms that
have been sub-classified based on histologic morphology [1]. The
four most common types of renal cortical neoplasms are clear cell
renal cell carcinoma (RCC) (63–89%,), papillary RCC (7–19%),
chromophobe RCC (2–6%), and oncocytoma (5–7%) [2,3]. Clear
cell tumors are most commonly associated with mutations in the
VHL tumor suppressor gene, familial and a subset of papillary
(type I) tumors are associated with dysregulation of the MET
proto-oncogene, and familial chromophobe tumors and oncocy-
tomas are associated with dysregulation of the BHD gene
[4,5,6,7,8].
Improved understanding of the genetic alterations and down-
stream molecular pathways of the histologic subtypes of renal
epithelial neoplasms has led to the development of targeted
molecular therapies and the tailoring of treatment and follow-up to
the subtype of the tumor. Knowledge of the aggressiveness of
histologic subtypes has aided in determining which patients may
be candidates for surveillance, as some non-clear cell subtypes are
associated with a more indolent course [3]. The FDA has
approved a number of targeted therapies for clear cell histology
and there are now promising clinical trials underway for papillary
histology [9,10].
The ability of sub-classification to aide in prognostication and
selection of appropriate treatment emphasizes the importance of
accuracy in the sub-typing of renal cortical tumors. Unfortunately,
diagnostic concordance between pathologists may be suboptimal.
This has recently been demonstrated by Kummerlin et al, who
showed that pathologists disagreed on the sub-classification of non-
clear cell tumors in up to 50% of cases [11]. While immunohis-
tochemistry is a valuable adjunct, most markers lack either
specificity or sensitivity, and even combinations of markers achieve
only 78–86% agreement with morphology-based sub-classification
[12].
In the current study, we used meta-analysis of gene expression
microarray data in an attempt to provide a link between
histopathologic diagnosis and molecular characteristics. By
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generate a large enough dataset to create a highly genereralizeable
set of signatures that represent the molecular correlate of the four
major sub-types of renal epithelial tumors.
Materials and Methods
Dataset search
The Gene Expression Omnibus (GEO) and Array Express
databases were searched for published microarray datasets
involving renal neoplasms. Search terms were: ‘‘kidney tumors,’’
‘‘kidney cancer,’’ and ‘‘renal cell carcinoma.’’ Selected datasets
included the four major types of renal cortical neoplasms: clear
cell, papillary, chromophobe, oncocytoma.
We included only datasets that utilized the Affymetrix platform
because this platform has demonstrated the best inter-institution
agreeability [13]. All studies processed samples similarly according
to the Affymetrix protocol. Datasets without a reference to a
publication describing the source of their tissue and IRB approval
were excluded. All studies without feature-level extraction output
files (.CEL files) were excluded in an attempt to prevent
confounding effects of different algorithms used in data pre-
processing [14]. Samples within each dataset with a histologic sub-
classification other than the four most common types of renal
epithelial tumors listed above were also excluded. If a sample was
noted to have features of another histology (i.e. clear cell with
papillary features), the sample was excluded. All the datasets
included in our training and validation samples were comprised of
snap-frozen samples from surgically removed primary tumors;
none of the studies used tissue from biopsies and none of the
samples were derived from metastatic sites.
Normalization and Filtering
Raw data from each dataset were imported into BRB array
tools (http://linus.nci.nih.gov/BRB-ArrayTools.html). Each data-
set was normalized independently using the GC-RMA algorithm
[15,16]. Each dataset was filtered so that genes were excluded
when less than 20% of expression data had at least a 1.5 -fold
change in either direction from gene’s median value, and when the
percent of data missing or filtered out exceeded 50%. Genes
passing the filtering criteria from each dataset were intersected
using the MergeMaid package for the R environment (http://
www.r-project.org) to identify common genes across multiple
datasets. Next, the ‘‘IntCor’’ function of MergeMaid was used to
perform integrative correlation analysis, whereby the correlation
of expression values across samples within one dataset, and across
multiple datasets, was evaluated [17]. All genes with an integrative
correlation coefficient of less than 0.5 were excluded. Thus, the
final list of genes included in our analysis represented the genes
with the least amount of variability across multiple datasets.
Algorithm Construction and Meta-Analysis
Multi-dimensional scaling was performed to determine the
differences in gene expression between datasets. Unsupervised
hierarchical clustering analysis was then performed on each
dataset independently to look for clustering patterns consistent
across multiple datasets. To maximize the differences between the
classes, and thus augment our predictive power, we sought to
create signatures that could be applied in an algorithm that would
mimic the natural clustering of samples in unsupervised analysis.
The creation of predictive signatures consisted of two steps as
previously described by Dobbin et al: 1) Differentially expressed
genes between classes were identified 2) The genes with the highest
discriminatory ability were selected from the differentially
expressed genes [18]. To identify differentially expressed genes
across multiple datasets, we employed a non-parametric ‘rank
product’ method implemented in the RankProd package for the R
environment [19]. This method has been shown to have higher
sensitivity and specificity than other types of meta-analytic tools for
microarrays [20]. Class comparison analysis using RankProd
identified differentially expressed genes between two classes in
each signature in the algorithm. We pre-specified a significant p-
value and pfp (‘‘percent false prediction’’ - a measure of false
discovery rate) as less than 0.001. Once differentially expressed
genes were identified, feature selection was performed using a pair-
based pairs method in BRB-array tools termed ‘‘greedy pairs’’
[15,21]. We set the number of pairs at 25 for each signature,
resulting in 50 gene signatures. We then decreased the number of
pairs to 12 (24 gene signatures) and then to 5 (10 gene signatures)
to determine the effect of decreasing the size of the signature to on
the accuracy of sub-classification.
Validation
We began validating our signatures by performing k-fold cross-
validation on the training set using the tools provided by BRB-
array tools [15]. We then searched the Gene Expression Omnibus
and Array Express databases using the same search criteria as
before to identify independent datasets that could be used for
validation. We included all datasets that met our criteria and that
were not used in the training set and again excluded all samples
without an associated reference describing the source of tissue and
IRB approval. We also validated our signatures on one of our own
datasets from a prior IRB-approved study [22]. Finally, we applied
our signatures in a sequential fashion according to our algorithm
and used the nearest centroid classification and the Bayesian
compound covariate predictors to evaluate the efficacy of the
signatures in our algorithm [15,23,24]. The error rate was
determined by misclassification at any step during the algorithm.
Results
Training set
A search of public databases identified four datasets that utilized
the Affymetrix platform and included samples with the four major
subtypes of renal epithelial tumors. The associated GEO accession
numbers are as follows: GSE 15641, GSE11024, GSE11151, and
GSE2109. One dataset, GSE2109 was excluded because it was not
associated with a peer-reviewed publication describing the source
of the samples. A summary of the three remaining datasets are
shown in Table 1 [25,26,27].
Table 1. Summary of datasets included in training set.
GEO ID GSE15641 GSE11024 GSE11151
PubMed ID* 16115910 18519660 19445733
Institution Beth Israel Van Andel Heidelberg
Chip type HG U133A HG U133Plus2.0 HG U133Plus2.0 Total
Clear cell 32 11 27 70
Papillary 11 10 19 40
Chromophobe 6 6 4 16
Oncocytoma 12 7 4 23
Total 61 34 54 149
*Pubmed ID of associated reference.
doi:10.1371/journal.pone.0021260.t001
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After normalization, 10,092, 19,601, and 23,870 genes passed
filtering criteria for GSE 15641, GSE11024, GSE11151, respec-
tively. Intersection of the genes using probe set IDs revealed 8,247
genes common to all three datasets after filtering. Integrative
correlation analysis identified 2,932 genes with an integrative
correlation coefficient less than 0.5. These genes were discarded,
leaving 5,315 genes to be used in the creation of our signatures.
Multi-Dimensional Scaling
Multi-dimensional scaling of samples revealed differences in
average gene expression values between datasets (Figure 1). The
differences between datasets indicated the need for statistical
methods that take the different sources of the data into account.
Algorithm Creation
Unsupervised clustering was performed independently for each
dataset and revealed consistent trends, as is illustrated in Figure 2A.
The first division separated datasets into samples of clear/papillary
and chromophobe/oncocytoma. Within these two primary
divisions, samples were separated into clusters of clear cell,
papillary, chromophobe, and oncocytoma at intermediate branch
points. Knowledge of clustering was used in creating the
algorithm; we applied our signatures at the branch points observed
in the natural clustering pattern in order to maximize the
differences between our samples. The algorithm (Figure 2B)
consisted of three signatures. The algorithm was applied to
samples in a two-step process using the first signature to separate
samples into clear cell/papillary or chromophobe/oncocytoma.
One of the two remaining signatures was then applied to the
sample depending on the results of the first signature, which
separated the sample into one of the four sub-types of renal
epithelial neoplasms.
Meta-Analysis and Signature Creation
Class comparison analysis was performed to identify differen-
tially expressed genes for each signature. Thus, three separate class
comparison analysis comparison analyses were performed using
the RankProd package. Class comparison analysis between clear/
papillary and chromophobe/oncocytoma identified 2,008 differ-
entially expressed genes. There were 1,408 differentially expressed
genes in the clear cell vs. papillary class comparison, and 432
differentially expressed genes in the chromphobe vs. oncocytoma
class comparison. The greedy pairs feature selection process chose
the most predictive genes among each list of differentially
expressed genes to create our final signatures.
Validation
K-fold cross-validation using the nearest centroid classifier in
BRB-array tools resulted in a correct classification rate of 99% for
the clear cell/papillary versus chromophobe/oncocytoma com-
parison, 98% for the clear cell vs papillary comparison, and 95%
for the chromophobe vs oncocytoma comparison. Search of the
Gene Expression Omnibus database for independent validation
datasets identified 4 independent datasets from three separate
institutions that met our search criteria [28,29,30,31]. We also
used ten of our own clear cell samples from patients with known
VHL mutations [22]. None of the samples in the validation
datasets were part of the original training set. We first applied our
50 gene signatures as shown in Figure 2B using the nearest
centroid classification predictor, and the correct classification rate
was recorded. A summary of the results of correct classification
based on our algorithm are shown in Table 2. Sixty-eight of the 72
samples were correctly classified. Of note, 49 of the total 52 (94%)
of the non-clear cell histologies were correctly classified. The size
of the signatures was decreased to 24 and then to 10 by decreasing
the number of pairs of genes in the ‘‘greedy-pairs’’ function. As
shown in Table 3, decreasing the number of genes in each
signature did not affect the misclassification rate during validation.
The results of the Bayesian compound covariate predictor are also
shown in Table 3. The percent of incorrectly classified samples
was lower with the Bayesian compound covariate predictor than
with the nearest centroid, but when the un-classified samples were
added, the two methods had similar results. Similar to the nearest
centroid predictor, the Bayesian compound covariate model
maintained discriminatory ability as the number of genes
decreases. The full composition of these signatures may be found
in Table S1.
Discussion
Until reliable biomarkers and molecular prognostic tools gain
widespread acceptance in the evaluation of renal masses,
histopathologic diagnosis remains an important factor in prognos-
tication, selection of treatment options, and inclusion in clinical
trials. Unfortunately, pathologists often disagree on sub-classifica-
tion of renal neoplasms based on morphology alone, with
discordance rates as high as 50% in the non-clear-cell histologies
[11]. This leads to reliance on immunohistochemistry, but
immunohistochemistry and morphology are often at odds [12].
In this study, we attempted to improve the molecular correlate to
morphology by developing gene expression signatures to aid in the
classification of the most common types of renal cortical
neoplasms.
Although sub-classification of renal neoplasms by molecular
signatures has been described previously, the methods used lacked
extensive external validation and were not amenable to being
translated into clinically useful tests [28,32]. In a study by Yang
Figure 1. Multi-dimensional scaling of gene expression profiles
from samples from different institutions. Red: GSE 11024, Green:
GSE 11151, Blue GSE 15641.
doi:10.1371/journal.pone.0021260.g001
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among samples from prior studies. Furge et al. split a sample of
cDNA arrays into two groups: a training set and a validation set. A
1018-set signature was used to predict the histology of their
validation set through the use of a nearest shrunken centroid
classifier [28]. While these studies demonstrate the feasibility of
molecular signatures in the sub-classification of renal tumors,
molecular signatures need to be reasonably sized and they need to
undergo rigorous external validation before they are clinically
useful [33].
A search of published datasets affords the opportunity to build
large datasets, but the differences in gene expression values
between datasets must be addressed. We limited our inter-dataset
variation by excluding all studies that did not utilize the Affymetrix
platform. Nevertheless, multi-dimensional scaling of the samples in
our study revealed obvious differences in gene expression values
between studies. Thus, we were obligated to ensure our statistical
analysis considered the differences between datasets in addition to
the differences between tumor types.
We took several measures to reduce the effects of inter-study
variation. First, we performed an integration correlation analysis
to discard all the genes with poor correlation and high variability
within a given study and across studies. Second, when identifying
differentially expressed genes to be included in our classifier, we
used meta-analytic techniques that took the differences between
datasets into account. This methodology may have the advantage
of identifying the genes that are most consistently associated with
the various histologies across multiple datasets, thus increasing the
generalizability of the signatures in our algorithm. Finally, to
maximize our power to distinguish between classes, we exploited
the differences inherent in the biology of these tumors by utilizing
knowledge of their natural clustering pattern. Interestingly, the
initial branching observed in unsupervised clustering of all three
datasets revealed clustering of clear and papillary RCC separate
Figure 2. Clustering of renal epithelial tumors. A) Natural clustering pattern of renal epithelial tumors, demonstrated with GSE11024. B)
Algorithm used to sub-classify renal epithelial tumors according to their molecular characteristics closely mimics the natural clustering pattern.
doi:10.1371/journal.pone.0021260.g002
Table 2. Summary of validation set and results of classification algorithm.
GEO ID# GSE8271 GSE12090 GSE7023 GSE6344 —
Institution V.A.I. Cornell V.A.I. M.C. N.C.I.
Pubmed ID* 18773095 17145811 17409424 17699851
Chip type HG U133Plus2.0 HG U133Plus2.0 HG U133Plus2.0 HG U133A HG U133Plus2.0 Total Correct Classification (%)
Clear Cell ———1 0 1 02 0 1 9 / 2 0 ( 9 5 % )
Papillary — — 14 — — 14 14/14 (100%)
Chromophobe 10 9 — — — 19 17/19 (90%)
Oncocytoma 10 9 — — — 19 18/19 (95%)
Total 20 18 14 10 10 72 68/72 (94%)
*Publication associated with dataset.
V.A. – Van Andle Institute.
M.C. – Mayo Clinic, Jacksonville.
N.C.I. – National Cancer Institute.
doi:10.1371/journal.pone.0021260.t002
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pattern may be explained by the site of origin of these tumors.
Chromophobe tumors and oncocytomas are derived from cells in
the distal tubule whereas clear cell and papillary tumors are
thought to arise from cells in the proximal tubule [34]. Within
each sub-branch, the tumors further differentiate based on their
histologic family. Therefore, while creating an algorithm, we
sought to maximize the differences between samples while
minimizing variance by applying our signatures at the first and
second branch points.
We validated our signatures using the most stringent methods
available to us [35]. Within our training set, we used a complete k-
fold cross-validation process, completely re-recreating our training
set each time samples were excluded [15]. However, because the
ultimate test of a signature is its performance on completely
independent samples, we also created a validation set with samples
that were not included in the development of our signatures. These
samples were procured at different centers, the tissue was handled
differently after procurement, the microarray experiments were
conducted in different laboratories, and the slides were read by
different pathologists. Despite these potential sources of error, our
classifier still maintained a 94% correct classification rate.
The ability to perform both cross-validation and independent
validation allowed us to study the effects of different classification
methods on the rate of correct classification. The two different
classifier types, nearest centroid and Bayesian compound covariate
predictor, had similar rates of misclassification/non-classification,
but their utility may differ depending on the purpose of the user. If
the goal is a dichotomous decision about molecular similarity
between a given sample and the molecular signatures described in
this study, the nearest centroid model is preferable. However, if
avoiding false negatives is a priority and the user is willing to
accept a number of non-classified samples, the Bayseisan
compound covariate predictor may be preferable. An added
advantage of the Bayesian compound covariate predictor is that
the user is able to evaluate a numeric probability of a sample’s
membership in a given class.
Our gene signatures were resilient to changes decreasing
signature size. Our ten gene signatures performed almost as well
as our 50 gene signatures, demonstrating the robust nature of our
analyses. Similar to the MammaPrintH signature platform that is
being evaluated to determine the use of gene signatures in early
stage breast cancer patients who may benefit from adjuvant
chemotherapy, our signatures may potentially be used in a clinical
setting [36]. We are considering a clinical trial to test the use of our
algorithm in clinical practice, and the potential utilities are
numerous. It may be used as a helpful adjunct to pathologists
when the diagnosis are not obvious, it may improve the diagnostic
accuracy of percutaneous renal biopsies (when the paucity of the
tissue limits adequate evaluation of morphologic patterns), and it
may help direct treatment options. For example, separating benign
oncocytomas that may safely be observed from chromophobe
tumors with malignant potential may be aided with the use of our
signatures. Of most importance, our potential ability to achieve
correct diagnosis in the majority of cases is intriguing and
promising.
While the purpose of the analysis was to identify the transcripts
most useful in differentiating different histologic subtypes,
evaluation of the lists of transcripts revealed several interesting
findings. First, the genes coding for some of the traditional
immunohistochemical markers for differentiating tumors were
found within the signatures. For example, in the 50 gene signature
that differentiated clear/papillary from chromophobe/oncocyto-
ma, the clear cell marker Vimentin was identified. In the 25 gene
signature that differentiated chromophobe from oncocytoma, the
chromophobe-specific marker Cytokeratin 7 was included [34].
Thorough evaluation of each of the genes in the signatures is
outside the scope of this study, although we did note that several of
the genes included had a known role in oncogenesis. For example,
PAX-8 was listed as over-expressed in clear cell tumors relative to
papillary. PAX-8 has been implicated in Wilm’s tumors [37].
SCRN1, a marker of colorectal cancer, was also over-expressed in
ccRCC relative to papillary [38]. Some of the genes in the
signatures may be ‘‘observers’’ rather than ‘‘drivers’’. For example,
the over-expression of aquaporin 6 in chromophobe tumors
relative to oncocytomas is unlikely to have any direct effect on
tumor growth or invasion, but is nonetheless a good marker - this
is the second study to show differential expression of this gene
between chromophobe RCC and oncocytomas [39].
We acknowledge several limitations of this study. First, while the
study includes the most common types of renal cortical tumors,
not all histologic subtypes are represented in our model. For
example, we excluded collecting duct RCC, clear cell RCC with
papillary features, and tubulo-papillary RCC. We felt that most of
these sub-types are either very rare or represent heterogeneous
histologies. We also did not separate papillary tumors into type I
and type II. These tumors may represent a continuum rather than
separate entities, and papillary type II may include eosinophilic
tumors of many origins [40]. We also did not performed analysis of
normal renal parenchyma. Normal renal parenchyma can be
readily distinguished from a solid renal tumor on H&E stain.
Therefore, we focused on differentiating different types of RCC.
Furthermore, while we validated the robustness of this signature
by examining the performance of our signature in outside datasets,
the true performance of the signature will have to be confirmed in
a set of unclassified renal cortical neoplasms. Indeed, this may
Table 3. Results of validation with multiple methods and multiple signature sizes.
NC* Training NC* Validation BCCP** Training BCCP** Validation
Misclassification 50 genes 2.7% 5.6% 2.0% 4.2%
Misclassification 24 genes 1.3% 6.9% 2.0% 4.2%
Misclassification 10 genes 2.7% 5.6% 1.3% 5.6%
Non-classified 50 genes — — 0.7% 1.3%
Non-classified 24 genes — — 2.0% 2.7%
Non-classified 10 genes — — 6.0% 4.2%
*NC – Nearest Centroid.
**BCCP – Bayesian Compound Covariate Predictor.
doi:10.1371/journal.pone.0021260.t003
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did not incorporate stage and grade of the tumors into our
algorithm as this information was not available for all studies.
While the lack of centralized pathology review may be
considered as a limitation of our study, it is an inherent feature
of this study that may also be its strength, since the samples
analyzed were derived from multiple institutions in two countries.
Our 94% accuracy when validated on external datasets is likely
due to the use of data from multiple sources making our results
more generalizable. The strong performance of our signature even
in the non-clear histologic subtypes is best explained by the fact
that we were not evaluating the genes that correlated with a
histologic subtype defined by one pathologist, but rather the
integration of molecular profiling with morphology as determined
by multiple pathologists at various academic institutions.
We hope that our future studies will help address the current
shortcomings in subclassification of renal cortical tumors, support
the clinical utility of our algorithm, and move the field closer
towards personalized medicine for patients with renal cortical
neoplasms.
In summary, the use of meta-analytic techniques has facilitated
the creation of signatures that have accurately differentiated renal
cortical neoplasms. Sequential application of three signatures,
according to an algorithm that utilized the natural differences in
gene expression between tumor subtypes, correctly classified renal
epithelial tumors from five institutions with 94% accuracy. Our
algorithm may potentially be used as a adjunct for pathologists
when the diagnoses are not obvious in order to improve the
diagnostic accuracy of percutaneous renal biopsies and to help
direct treatment options.
Supporting Information
Table S1 Gene Signature. ccRCC - Clear Cell Renal Cell
Carcinoma; pRCC - Papillary Renal Cell Carcinoma; chRCC -
Chromophobe Renal Cell Carcinoma; ONCO – Oncocytoma.
(XLS)
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